Long considered mainly for its role in acne, Cutibacterium acnes is now recognized as a complex member of the skin microbiome. Naturally present on the skin, this bacterial species includes several phylotypes whose biological properties may differ, particularly in terms of host interaction, production of virulence-associated factors, and pro-inflammatory potential. This diversity opens up valuable perspectives for the preclinical evaluation of cosmetic actives targeting acne-prone skin.
At Smaltis, we support ingredient laboratories and finished product developers in the microbiological exploration of this topic. Our expertise is based on controlled bacterial culture, the handling of demanding strains, and the development of tailored in vitro protocols adapted to screening, active comparison, or mechanistic investigation objectives.
We can work with different C. acnes phylotypes to assess the effects of ingredients or formulations on bacterial growth, viability, or selected functional properties. This approach makes it possible to go beyond a simple global antimicrobial test by taking into account strain specificity and the complexity of the skin microbiome. It can also be complemented by the preparation of C. acnes-derived products — such as biomass, supernatants, or cellular fractions — intended to study their impact on skin cell models, for example in the context of inflammatory responses or mechanisms involved in the skin–microbiome balance.
Positioned upstream of clinical studies, these in vitro approaches represent a valuable tool to guide product development, document a scientific rationale, and better understand interactions between skin bacteria, cosmetic ingredients, and skin cells.
At the interface between microbiology, cell biology, and cosmetic innovation, Smaltis provides its know-how to support robust, customized, and scientifically grounded preclinical evaluation.
Contact
+33(0)3 81 84 01 42
contact@smaltis.com
